Valued at USD 27.32 Bn in 2024, the market is projected to reach USD 47.76 Bn by 2033, growing at a 6.4% CAGR. Europe holds the largest share, while Asia-Pacific grows fastest. The report profiles 15 companies.
The global CD antigen cancer therapy market was valued at USD 27.32 Bn in 2024 and is projected to reach USD 47.76 Bn by 2033, growing at a CAGR of 6.4%. Europe is the largest regional market and Asia-Pacific is growing fastest.
Reports Description
As per the current market research conducted by the CMI Team, the global CD Antigen Cancer Therapy Market is expected to record a CAGR of 6.4% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 27,324.6 Million. By 2033, the valuation is anticipated to reach USD 47,756.1 Million.
The CD antigen cancer therapy market encompasses the development and commercialization of therapies targeting specific cell surface proteins, known as CD antigens, implicated in cancer progression. These therapies include monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bi-specific T-cell engagers (BiTEs).
By selectively targeting cancer cells while sparing healthy tissue, CD antigen therapies offer the potential for improved treatment efficacy and reduced toxicity. With ongoing research into novel CD antigens and innovative therapeutic approaches, the market continues to expand, addressing unmet medical needs and driving advancements in cancer care.
CD Antigen Cancer Therapy Market - Significant Growth Factors
Advancements in Immunotherapy: The increasing understanding of immune system interactions with cancer cells has propelled the development of CD antigen cancer therapies. Advancements in immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, have driven the demand for CD antigen-targeted treatments.
Growing Incidence of Cancer: With the rising prevalence of cancer worldwide, there's a growing demand for effective treatment options. CD antigen cancer therapies offer targeted approaches that can improve treatment outcomes, leading to increased adoption and market growth.
Technological Innovations: Advances in biotechnology and genetic engineering have facilitated the development of novel CD antigen-targeted therapies, such as antibody-drug conjugates (ADCs) and bispecific antibodies. These technological innovations drive the expansion of the CD antigen cancer therapy market.
Shift Towards Personalized Medicine: There's a growing trend towards personalized medicine in oncology, driven by the need for more effective and tailored treatment options. CD antigen therapies can be customized based on individual patient profiles, offering opportunities for precise and targeted cancer treatment.
Expanding Indications: There is an opportunity to explore new indications and expand the use of CD antigen cancer therapies across various cancer types. By identifying additional CD antigens and their roles in different cancers, companies can develop therapies for unmet medical needs and broaden their market reach.
CD Antigen Cancer Therapy Market - Mergers and Acquisitions
The CD Antigen Cancer Therapy Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the CD Antigen Cancer Therapy Market include:
In 2021, TUKYSA® (tucatinib) gained approval in the U.S. and other nations for specific HER2+ metastatic breast cancers, in combination with trastuzumab and capecitabine. It marks the third approved therapy and the first wholly owned medicine in this context.
In 2022, Seagen's partnership with Pfizer's Array BioPharma involves the manufacture, development, and sale of Tukysa, a medication for breast and colorectal cancer. This collaboration strengthens Seagen's position in the oncology market and expands treatment options for cancer patients.
In 2023, Gilead Sciences, Inc. obtained FDA approval for Trodelvy to treat inoperable locally advanced or metastatic breast cancer in adults. This approval expands treatment options and is expected to improve outcomes for patients with breast cancer, addressing unmet medical needs in the market.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the CD Antigen Cancer Therapy Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
CD Antigen Cancer Therapy Market - Significant Threats
The CD Antigen Cancer Therapy Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
Resistance and Relapse: One significant threat is the development of resistance to CD antigen-targeted therapies, leading to treatment failure and disease relapse. Tumor cells can evolve mechanisms to evade therapy, reducing treatment efficacy and limiting long-term patient outcomes.
Toxicity and Side Effects: Another threat is the potential for toxicity and adverse side effects associated with CD antigen-targeted therapies. While these treatments are designed to selectively target cancer cells, they may also impact healthy tissues expressing the targeted CD antigens, leading to off-target effects and treatment-related complications.
Competition and Market Saturation: The CD antigen cancer therapy market is highly competitive, with numerous players developing similar therapies targeting overlapping CD antigens. Intense competition can lead to pricing pressures, reduced market share, and challenges in differentiating products, posing a threat to profitability and sustainability.
Regulatory and Reimbursement Challenges: Regulatory hurdles, including stringent approval processes and evolving safety requirements, present a significant threat to CD antigen cancer therapies. Delays or failures in obtaining regulatory approvals can hinder market entry and limit patient access to innovative treatments. Additionally, challenges in securing reimbursement for novel therapies may impact market adoption and commercial success.
Category-Wise Insights
By Type of CD Antigen Targeted:
CD19: CD19-targeted therapies, such as CAR-T cell therapy and monoclonal antibodies, are used primarily in the treatment of B-cell malignancies, including leukemia and lymphoma. Trends include the development of novel CAR-T constructs with enhanced persistence and efficacy, and the exploration of combination therapies.
CD20: CD20-targeted therapies, predominantly monoclonal antibodies like rituximab, are utilized in B-cell lymphomas and leukemias. Trends include the development of next-generation anti-CD20 antibodies with improved efficacy and reduced immunogenicity, as well as combination strategies with chemotherapy and immunomodulators.
CD30: CD30-targeted therapies, including antibody-drug conjugates (ADCs) like brentuximab vedotin, are employed in Hodgkin lymphoma and other CD30-expressing lymphomas. Trends include the exploration of novel ADC payloads and combination approaches, as well as the investigation of CD30-targeted immunotherapies such as CAR-T cells.
CD33: CD33-targeted therapies, such as gemtuzumab ozogamicin, are utilized in acute myeloid leukemia (AML). Trends include the development of next-generation CD33-targeted ADCs with improved therapeutic indices and reduced off-target effects, as well as combination strategies with chemotherapy and targeted agents.
CD38: CD38-targeted therapies, like daratumumab, are primarily used in multiple myeloma. Trends include the expansion of CD38-targeted therapies into other hematologic malignancies and solid tumors, the development of subcutaneous formulations for improved convenience, and combination regimens with immunomodulatory drugs and proteasome inhibitors.
CD70: CD70-targeted therapies, such as antibody-drug conjugates and CAR-T cell therapies, are under investigation for various malignancies, including renal cell carcinoma and non-Hodgkin lymphoma. Trends include the advancement of CD70-targeted immunotherapies into clinical trials, with a focus on identifying optimal treatment strategies and patient populations.
Others: This category encompasses CD antigens beyond CD19-CD70, including emerging targets like CD123 and CD44. Trends include the exploration of novel CD antigens as therapeutic targets, the development of innovative antibody constructs and immunotherapies, and the identification of biomarkers predictive of response to CD antigen-targeted therapies.
Global CD Antigen Cancer Therapy Market 2024–2033 (By Type of CD Antigen Targeted)
Monoclonal Antibodies (mAbs): Monoclonal antibodies are proteins designed to target specific CD antigens on cancer cells, triggering immune responses against tumors. Trends include the development of novel mAbs targeting emerging CD antigens, combination therapies with immune checkpoint inhibitors, and advancements in antibody engineering for improved efficacy.
Antibody-Drug Conjugates (ADCs): ADCs are monoclonal antibodies conjugated to cytotoxic drugs, delivering chemotherapy directly to cancer cells expressing CD antigens. Trends include the development of next-generation ADCs with improved payload delivery, site-specific conjugation technologies, and novel linker designs to enhance tumor targeting and reduce off-target toxicity.
Chimeric Antigen Receptor (CAR) T-cell Therapy: CAR T-cell therapy involves engineering patients' T-cells to express synthetic receptors targeting CD antigens, enabling potent anti-tumor immune responses. Trends include the expansion of CAR T-cell therapies beyond haematological malignancies, optimization of CAR designs for improved safety and efficacy, and the development of off-the-shelf CAR T-cell products.
Bi-specific T-cell Engagers (BiTEs): BiTEs are bi-specific antibodies designed to simultaneously bind CD antigens on cancer cells and T-cells, promoting tumor cell killing. Trends include the development of BiTEs targeting novel CD antigens, combination therapies with checkpoint inhibitors, and advances in BiTE engineering for enhanced potency and reduced immunogenicity.
Radioimmunotherapy, Immunotoxins: Radioimmunotherapy involves the use of radioisotopes conjugated to monoclonal antibodies to deliver targeted radiation to cancer cells expressing CD antigens. Immunotoxins are fusion proteins combining antibodies with cytotoxic agents, inducing cell death. Trends include the development of novel radioisotopes and toxins for improved tumor targeting and therapeutic efficacy.
By End User
Hospitals: Hospitals are primary providers of cancer treatment, including CD antigen therapies. Trends include the adoption of comprehensive cancer care programs integrating CD antigen therapies, investment in advanced oncology departments, and collaboration with research institutions for clinical trials.
Specialty Clinics: Specialty clinics focus on specific cancer types, offering targeted CD antigen therapies alongside supportive care services. Trends include niche specialization, patient-centered approaches, and integration of multidisciplinary care teams for personalized treatment plans.
Cancer Treatment Centers: Dedicated cancer treatment centers offer a range of CD antigen therapies supported by state-of-the-art facilities and expertise. Trends include an emphasis on evidence-based practices, patient advocacy, and the adoption of innovative technologies for precision oncology.
Research Institutes: Research institutes drive innovation in CD antigen cancer therapy through preclinical studies and clinical trials. Trends include translational research, biomarker discovery, and collaboration with industry partners for drug development and validation.
Report Scope
Feature of the Report
Details
Market Size in 2024
USD 27,324.6 Million
Projected Market Size in 2033
USD 47,756.1 Million
Market Size in 2023
USD 25,681.1 Million
CAGR Growth Rate
6.4% CAGR
Base Year
2023
Forecast Period
2024-2033
Key Segment
By Type of CD Antigen Targeted, Therapy Type, Cancer Type, End User and Region
Report Coverage
Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options
Request tailored purchasing options to fulfil your requirements for research.
CD Antigen Cancer Therapy Market - Regional Analysis
North America: In North America, trends in the CD antigen cancer therapy market include a strong emphasis on precision medicine and personalized oncology, with robust investments in genomic profiling and targeted therapy development. Additionally, there's a focus on collaborative research efforts between academia, industry, and government institutions to drive innovation and accelerate drug discovery and development processes.
Europe: In Europe, trends in the CD antigen cancer therapy market revolve around regulatory harmonization and streamlined approval processes to facilitate timely access to innovative therapies. There's also a growing focus on cost-effectiveness and value-based healthcare models, prompting the adoption of CD antigen therapies that demonstrate improved clinical outcomes and cost savings over traditional treatments.
Asia-Pacific: In the Asia-Pacific region, trends in the CD antigen cancer therapy market include increasing investments in healthcare infrastructure and oncology research, particularly in countries like China, Japan, and South Korea. There's a growing demand for affordable and accessible cancer treatments, driving the adoption of CD antigen therapies as part of comprehensive cancer care programs.
LAMEA (Latin America, Middle East & Africa): In LAMEA, trends in the CD antigen cancer therapy market are characterized by efforts to address healthcare disparities and improve access to innovative treatments in underserved regions. Governments and healthcare organizations are investing in capacity building, clinical trials infrastructure, and healthcare reforms to expand access to CD antigen therapies and improve cancer outcomes.
Global CD Antigen Cancer Therapy Market 2024–2033 (By Million)
Competitive Landscape – CD Antigen Cancer Therapy Market
The CD Antigen Cancer Therapy Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
Novartis AG
Roche Holdings AG
Bristol Myers Squibb Company
Gilead Sciences Inc.
Merck & Co. Inc.
Johnson & Johnson
Amgen Inc.
AbbVie Inc.
AstraZeneca PLC
Takeda Pharmaceutical Company Limited
Seattle Genetics Inc.
Biogen Inc.
Celgene Corporation
Genmab A/S
Immunomedics Inc.
Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the CD antigen cancer therapy market are leveraging innovation and development to establish their presence. Companies like Adaptimmune Therapeutics and Fate Therapeutics are pioneering novel approaches such as engineered T-cell therapies and induced pluripotent stem cell (iPSC)-derived cell therapies.
Dominating the market are key players like Novartis AG, Roche Holdings AG, and Bristol Myers Squibb Company, with extensive R&D investments, established product pipelines, and strategic partnerships. They lead through a combination of clinical success, regulatory approvals, and strong market presence, securing their dominance in the industry.
Which are the driving factors of the CD Antigen Cancer Therapy Market?
The key factors driving the Market are Advancements in Immunotherapy, Growing Incidence of Cancer, Technological Innovations, Shift Towards Personalized Medicine, Expanding Indications.
Which type led the CD Antigen Cancer Therapy market?
The "Monoclonal Antibodies (mAbs)" category dominated the market in 2023.
Who are the key players in the CD Antigen Cancer Therapy market?
The key players in the market are Novartis AG, Roche Holdings AG, Bristol Myers Squibb Company, Gilead Sciences Inc., Merck & Co. Inc., Johnson & Johnson, Amgen Inc., AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Seattle Genetics Inc., Biogen Inc., Celgene Corporation , Genmab A/S, Immunomedics Inc., Others.
Which region held the largest market share in the CD Antigen Cancer Therapy market?
"Europe" had the largest share in the CD Antigen Cancer Therapy Market.
What is the growth rate of the CD Antigen Cancer Therapy market?
The global market is projected to grow at a CAGR of 6.4% during the forecast period, 2024-2033.
How much is the CD Antigen Cancer Therapy market?
The CD Antigen Cancer Therapy Market size was valued at USD 27,324.6 Million in 2024.
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
